| Literature DB >> 35324735 |
Yuan Lei1, Jiahua Guo1, Qiqi Chen1, Jiezhang Mo2, Yulu Tian1, Hisato Iwata3, Jinxi Song1.
Abstract
Pravastatin, used for lowering cholesterol and further decreasing blood lipid, has been frequently detected in the contaminated freshwaters, whereas its long-term exposure effects on non-target aquatic invertebrates remains undetermined. Therefore, the purpose of this study was to evaluate the toxic effects of pravastatin (PRA) with the concentration gradients (0, 0.5, 50, 5000 μg/L) on a model water flea Daphnia magna (D. magna) over 21 d based on phenotypic and genome-wide transcriptomic analyses. After 21 d, exposure to PRA at 5000 μg/L significantly reduced the body length and increased the number of offspring. The 76, 167, and 499 differentially expressed genes (DEGs) were identified by using absolute log2 fold change < 1 and adj p < 0.05 as a cutoff in the 0.5, 50, and 5000 μg/L PRA treatment groups, respectively. Three pathways, including xenobiotic metabolism, insect hormone biosynthesis pathway, and energy metabolism were significantly (p < 0.05) enriched after exposure to PRA. These suggested that the upregulation of genes in insect biosynthetic hormone pathway increased the juvenile hormone III content, which further reduced the body length of D. magna. The positive effect of methyl farnesoate synthesis on the ovarian may result in the increased number of offspring. Furthermore, energy tended to be allocated to detoxification process and survival under stress conditions, as the amount of energy that an individual can invest in maintenance and growth is limited. Taken together, our results unraveled the toxic mechanism of cardiovascular and lipid pharmaceuticals in aquatic invertebrate.Entities:
Keywords: body length; juvenile hormone; methyl farnesoate; reproductive toxicity; statins
Year: 2022 PMID: 35324735 PMCID: PMC8952691 DOI: 10.3390/toxics10030110
Source DB: PubMed Journal: Toxics ISSN: 2305-6304
Figure 1Inhibition rate of D. magna exposed to different PRA concentrations for 48 h (n = 8).
Figure 2Growth parameters in D. magna after 21 d exposure to pravastatin sodium (PRA): (a) Body length growth in D. magna during 21 d test; (b) Offspring per each clutch in D. magna during 21d PRA exposure test; (c) The average number of reproduction (left) and molting (right) of each D. magna during 21 d PRA test. C, L, M and H represent the control, low, medium and high PRA treatment groups, respectively. An asterisk (*) indicates that the parameters of PRA treatment groups are significantly different from control (p < 0.05; n = 60).
Figure 3Transcriptomic profiling of D. magna following a 21 d exposure to pravastatin sodium (PRA): (a) Correlation analysis of patterns of gene expression level in control and three treatment groups; (b) A heatmap of centered and scaled FPKM values of DEGs in controls and three treatment groups; (c) Principal component analysis (PCA) of FPKM profiles in three treatment groups; (d) Venn diagram of the number of DEGs in three treatment groups. L, M and H represent the low, medium and high PRA treatment groups, respectively.
List of crucial biological pathways disrupted by PRA exposure (p < 0.05).
| Category | Pathway | Up-Gene | Down-Gene | |
|---|---|---|---|---|
| C-vs-L | ||||
| Metabolism | Glutathione metabolism | 1.6 × 10−3 |
|
|
| Metabolism | Insect hormone biosynthesis | 4.4 × 10−3 |
|
|
| Metabolism | Drug metabolism—cytochrome P450 | 4.0 × 10−4 |
|
|
| Metabolism | Drug metabolism—other enzymes | 3.4 × 10−2 |
|
|
| Metabolism | Metabolism of xenobiotics by cytochrome P450 | 4.9 × 10−4 |
|
|
| C-vs-M | ||||
| Metabolism | Insect hormone biosynthesis | 8.5 × 10−3 |
|
|
| C-vs-H | ||||
| Metabolism | Glutathione metabolism | 5.8 × 10−3 |
|
|
| Metabolism | Insect hormone biosynthesis | 5.2 × 10−4 |
|
|
| Organismal Systems | Pancreatic secretion | 2.7 × 10−3 |
|
|
| Organismal Systems | Protein digestion and absorption | 6.36 × 10−7 |
|
|